An experimental pill called enlicitide slashed levels of low-density lipoprotein (LDL) cholesterol, commonly known as "bad" ...

Patients with severe hypercholesterolemia who are unresponsive to a number of lipid-lowering therapies, including a PCSK9 inhibitor and high-dose statin, can have a significant reduction in ...

Pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) are produced in large quantities locally in the joints and subsequently enter the bloodstream. TNF-α and IL-6 may promote LDL metabolism by ...

The U.S. government's premier research body has made an important discovery that could help create new drugs to lower "bad" cholesterol, and hopefully prevent heart attacks and stroke. But the ...

High levels of low-density lipoprotein (LDL) cholesterol can cause artery blockages and diseases like heart attacks and strokes. Further, it raises the risk of cardiovascular disease (CVD). Thickened ...

Such a puzzle since the patient had neither CVD risk factors nor atherosclerotic changes ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials RAHWAY, N.J.--(BUSINESS WIRE)- ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is highly expressed in adult hepatocytes. PCSK9 binds to and promotes the degradation of the low-density lipoprotein (LDL) receptor, thereby ...

In today’s Health Alert, a promising new type of pill dramatically lowered artery-clogging cholesterol in a study of patients at high risk for heart attacks.